With the challenge of delivering clinically useful doses of STAT3 inhibitors into the brain, our findings will also motivate efforts to develop new generation, blood-brain barrier-permeable STAT3 inhibitors that can subsequently be combined with CDK4/6 inhibitors for effective GBM eradication. This evidence concerns the gene CDK4 and glioblastoma.